23 Jul, 2026
The global upstream bioprocessing market size reached USD 21.54 billion in 2025 and is anticipated to grow from USD 24.06 billion in 2026 to USD 58.34 billion by 2034, expanding at a CAGR of 11.71% over the forecast period from 2026 to 2034.
Upstream bioprocessing refers to the initial stages of the biomanufacturing process, where biological materials are cultivated and produced. This phase involves using living organisms, such as cells, to produce valuable products like vaccines, therapeutic proteins, and other biopharmaceuticals. The process typically begins with the selection of a suitable host organism, followed by cell culture, fermentation, and the optimization of environmental factors like temperature, pH, and nutrient supply to maximize the yield and quality of the desired product.
The growing demand for cell and gene therapies is driving significant advancements in upstream bioprocessing, especially in scalable bioreactor systems and optimized cell culture media. As the need for biologics, including cell and gene therapies, continues to rise, manufacturing facilities are expanding to meet these demands.
For instance, in October 2022, Lonza expanded its cell and gene therapy manufacturing facility in Geleen, Netherlands, to boost viral vector production. This expansion highlights the increasing demand for efficient upstream bioprocessing solutions that can support the production of advanced biologics, further fueling the market's growth.
The increasing demand for flexible and scalable biomanufacturing solutions has led to the growing adoption of modular and prefabricated bioprocessing facilities. These facilities offer advantages such as rapid deployment, cost-efficiency, and adherence to GMP standards, making them particularly suitable for the production of biologics and gene therapies.
Such innovations present valuable opportunities for biopharma companies, enabling them to quickly adapt to market needs, maintain regulatory compliance, and meet the rising global demand for high-quality biologics.
North America remains a dominant force in the global upstream bioprocessing market, bolstered by its robust biopharmaceutical ecosystem, substantial R&D investments, and cutting-edge manufacturing infrastructure. The region is home to a high concentration of biologics manufacturers, with major players like Amgen, Pfizer, and Moderna leading the charge in innovation. Key biotech hubs, such as Boston and California’s Bay Area, facilitate collaborative research and process development. Moreover, government support, including the U.S. FDA’s initiatives to advance biomanufacturing and the NIH’s funding for cell and gene therapy programs, strengthens North America’s position as the market leader.
sales@straitsresearch.com